Moderator: **Harry Glorikian**, General Partner, Scientia Ventures, Author,
MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market

	AI Case Studies in Discovery & Clinical Development **October 26, 2020**
10:30 - 11:00	**Target Identification, Validation & Molecule Generation** **Martin Akerman**, CTO, Envisagenics **Spyro Mousses**, CEO, Systems Oncology
11:00 - 11:30	**How to Approach Predictive ADMET Modeling and Maximize its Impact on Drug Discovery Projects** **Barun Bhhatarai**, Investigator, Novartis Institutes for BioMedical Research (NIBR) **Marcel Hop**, Vice President, Drug Metabolism and Pharmacokinetics, Genentech • Retrospective analysis of results in ADMET • The importance of culture – getting the chemistry teams in the right mindset, using the advanced AI/ML technologies, and willing to incorporate the predictions and move ahead using models – use cases • ADMET models and technologies are better so what's the future for solving the potency and selectivity challenges?
11:30 - 11:45	**Spotlight Presentations** **Tackling the "Small Data Problem": Integration and Harmonization Strategies to Unlock the Potential of Clinical Trial Datasets** **Rafael Rosengarten, PhD**, CEO, Genialis **Leveraging AI to Aggregate Healthcare Data and HCP Data** **Ariel Katz**, Co-Founder, H1
11:45 - 12:30	**Leader Perspectives in Clinical Development: Achieving Consistency in Validating & Operationalizing the AI/ML Automation Efforts Transforming Biopharma** **Neal Grabowski, MEng, MBA,** Director, Safety Data Science, AbbVie; Intelligent Automation Opportunities (IAO) in PV Workstream Lead, TransCelerate BioPharma, Inc. (moderator) **Danielle Abatemarco, MSc,** Scientific Publications Lead, WorldWide Patient Safety, Bristol-Myers Squibb; Intelligent Automation Opportunities (IAO) Workstream Member, TransCelerate BioPharma, Inc. **Andrew Bate, PhD,** Head of Safety Innovation and Analytics, GSK; Pharmacovigilance Steering Committee Member, TransCelerate BioPharma, Inc. Although certain intelligent automation technologies have been used in some PV areas for years (e.g., rule-based software, auto-coding, auto-narrative generation, etc.), rapid development of newer technologies (e.g., machine learning, natural language processing) has outpaced some PV regulations. Therefore, continued innovation will be more likely and ultimately more successful if companies and 3rd party developers can be reasonably assured they have adequately validated their systems and automated processes. This session will feature a panel of leaders discussing emerging forces that are shaping the global future of biopharma, and how intelligent automation and AI is transforming how we work. The session will include discussions on the current technology landscape in biopharma, particularly in pharmacovigilance; intelligent automation opportunities in PV; and propose consideration for validating intelligent automation technologies in PV to promote inspection readiness and inform third-party development.
12:30 - 1:00	**Unconventional AI/ML for the Biomedical Sciences** **Thomas W. Chittenden, PhD, DPhil, PStat,** Chief Data Science Officer, Genuity Science • Understanding driver biology and Identifying causal drug targets that are driving disease ideology • Going after the means and the capabilities to drive more effective therapeutics with far fewer associated side effects • Quantum computing approaches to analysis of multi-omic data